Stock MYGN MYRIAD GENETICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Market Closed - Nasdaq
Other stock markets
 16:30:01 2024-05-06 EDT 		5-day change 1st Jan Change
19.97 USD +2.57% Intraday chart for Myriad Genetics, Inc. +0.86% +4.34%
03-20 Myriad Genetics Gets US Patent for SneakPeek Snap Device MT
02-27 Transcript : Myriad Genetics, Inc., Q4 2023 Earnings Call, Feb 27, 2024

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024
GL
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel Prenatal Screen
AQ
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
GL
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
GL
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
GL
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
AQ
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
GL
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
AQ
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
GL
Myriad: Q4 Earnings Snapshot
AQ
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance
GL
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance
AQ
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
GL
Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
GL
Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health
GL
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
GL
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
AQ
Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
GL
Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
GL
Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MYGN Stock
  4. News Myriad Genetics, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW